Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2021 | $10.00 | Buy | EF Hutton |
EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu
MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025. On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with
MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica
SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)
Watch the "What This Means" video here Featuring Company's second-generation T-Cell Engager program and advantages over first-generation Company's T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice
Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. ("Wugen") on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[1], driving unprecedented investment in longevity solutions as populations worldwide confront global demographics where those aged 60+ will surge from 900 million in 2015 to 2 billion by 2050[2]. These macro forces position Avant Technologies, Inc. (OTCQB:AVAI), HCW Biologics Inc. (NASDAQ:HCWB), Solid Biosciences Inc. (NASDAQ:SLDB), ProMIS Neuorsciences, Inc. (NASDAQ:PMN), and uniQure N.V. (NASDAQ:QURE).
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
4 - HCW Biologics Inc. (0001828673) (Issuer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
8-K - HCW Biologics Inc. (0001828673) (Filer)
10-Q - HCW Biologics Inc. (0001828673) (Filer)